REGN Q4 2021 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5.0B+104.4% YoY

Gross Profit

$3.9B78.7% margin

Operating Income

$2.6B53.3% margin

Net Income

$2.2B45.0% margin

EPS (Diluted)

$19.69

QoQ Revenue Growth

+43.4%

Cash Flow

Operating Cash Flow

$2.4B

Free Cash Flow

$2.2B

Stock-Based Comp.

$188M

Balance Sheet

Total Assets

$25.4B

Total Liabilities

$6.7B

Stockholders' Equity

$18.8B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.0B	$2.4B	+104.4%
Gross Profit	$3.9B	$2.0B	+93.9%
Operating Income	$2.6B	$1.2B	+126.2%
Net Income	$2.2B	$1.1B	+94.0%

Revenue Segments

Product

$4.0B98%

Product and Service, Other

$86M2%